Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

Abstract Background Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases. Treatment with peptide receptor radionuclide therapy (PRRT) shows a hi...

Full description

Bibliographic Details
Main Authors: Arthur J. A. T. Braat, Dik J. Kwekkeboom, Boen L. R. Kam, Jaap J. M. Teunissen, Wouter W. de Herder, Koen M. A. Dreijerink, Rob van Rooij, Gerard C. Krijger, Hugo W. A. M. de Jong, Maurice A. A. J. van den Bosch, Marnix G. E. H. Lam
Format: Article
Language:English
Published: BMC 2018-06-01
Series:BMC Gastroenterology
Subjects:
NET
Neuroendocrine tumour
Liver metastasis
Radioembolization
Holmium-166
PRRT
Online Access:http://link.springer.com/article/10.1186/s12876-018-0817-8

Internet

http://link.springer.com/article/10.1186/s12876-018-0817-8

Similar Items